PDCD1 and urinary bladder cancer: Many ICB therapeutic response prediction biomarkers have also been developed in other cancers and subsequently applied to bladder cancer anti‐PD‐1/PD‐L1 therapy as mentioned early (see supplementary material, Table S2), such as TML, initially identified in melanoma, lung, and colon cancer studies 61, 195, 196, 197, 198.